

Valens GroWorks Corporation

13:50 18 Jun 2019

Buds & Duds: Cannabis stocks nudge up, but Valens shares soar on Tier 1 life sciences issuer news

Cannabis stocks perked up on Monday after a tough week last week across North American markets.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was up 1.1% to 236.6 points on Tuesday. The Horizons Marijuana Life Sciences Index ETF was up 1% to C\$18.73. The OTCQX Cannabis Index was up 0.7% at 719.60 points.

Buds

Valens GroWorks Corp (CSE:VGW) (OTCMKTS:VGWCF) announced Monday that it has received conditional approval to list on the TSX Venture Exchange as a Tier 1 life sciences issuer.

Shares of Valens were on the rise Tuesday, up 8.1% at C\$3.73 in Toronto, up 2.9% at US\$2.80.

The listing is subject to certain requirements of the TSX Venture, in accordance with the terms of its conditional approval letter dated June 14, 2019.

"We are very pleased to have received conditional approval from the TSXV and believe that this listing will provide the company and its shareholders with many advantages, including greater visibility and enhanced market access for Canadian and international investors," says Tyler Robson, CEO of Valens GroWorks Corp.

The company said the common shares will trade under the trading symbol VGW.

READ: Valens gets approval to list as Tier 1 life sciences issuer
ICC International Cannabis Corp (CSE:WRLD.U) (OTCMKTS:WLDCF) took a step closer to making its cannabis facility fully operational with the completion of a technical feasibility study, the company announced Tuesday.

The 150,000-square foot facility located in Møldrup, Denmark will be used for cannabis cultivation, processing and manufacturing.


Investors sent ICC's shares up 5.6% on Tuesday morning in Canada at C\$0.19, and 9.1% higher on the OTC Markets to US\$0.19.

READ: ICC International Cannabis says Danish facility could produce 20 million grams of dried cannabis flower per year
Other gainers Tuesday included cannabis company MariMed Inc (OTCQB:MRMD), which saw shares rise 10.5% at US\$2.31.

Price: 3.06

Market Cap: \$377.68 m

1 Year Share Price Graph



July 2019 September 2019 November 2019

Share Information

Code: VGW

Listing: TSX-V

52 week	High	Low
	4.69	2.6

Sector: Cannabis

Website: www.valensgroworks.com

Company Synopsis:

Valens GroWorks Corp. is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white label product development.

action@proactiveinvestors.com

Yesterday, the firm announced a statement regarding recent stock volatility and a change to its board of directors after its management was "concerned last week that the share price volatility appeared to coincide with the recent resignation of a member of its board of directors, as outlined in a recent Form 8K filing." The company explained that the former director had no involvement in the day to day management or operations of the company and "his departure had been anticipated for some time."

Duds

Laggards Tuesday included Auxly Cannabis Group Inc (CVE:XLY) (OTCMKTS:CBWTF), which saw its stock trip and stumble on Tuesday. The company has operations across Canada and Uruguay,

Shares were down 6.6% at US\$0.53 in New York. The firm hasn't released any new news.

Other laggards Tuesday included Canopy Rivers Inc (CVE:RIV), which was on the decline, down 3.5% at US\$2.73 in New York, off 4.9% at C\$3.65 in Toronto.

The firm hasn't released any news. However, last week it announced it was granting incentive stock options under the company's stock option plan to certain executives to purchase 1.2 million voting shares at a price of \$3.87 per subordinate voting share, exercisable for a period of five years.

Contact Katie Lewis at katie@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Valens GroWorks Corporation named herein, including the promotion by the Company of Valens GroWorks Corporation in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).